Shiva Malek
Novartis Institutes for Biomedical Research, Boston, USA
Dr. Shiva Malek is Global Disease Area Head of Oncology at the Novartis Institutes for BioMedical Research, the preclinical and early clinical innovation engine of Novartis. Previously, Dr. Malek was Vice President of Discovery Oncology at Genentech, accountable for oncology research and the company’s targeted therapeutics oncology research portfolio. She joined Genentech in 2006 as one of the first scientists in its newly established small-molecule discovery team, and previously held positions of increasing responsibility at Vertex Pharmaceuticals and Exelixis. Dr. Malek is a world leader in RAS/RAF biology whose work has been critical to the discovery and validation of drug targets across multiple kinase signaling pathways in cancer. In 2021, she was selected by Endpoints as one of 20 top women leaders in biopharma R&D. She earned her Ph.D. in biochemistry from the University of California San Diego.
Dr. Shiva Malek is Global Disease Area Head of Oncology at the Novartis Institutes for BioMedical Research, the preclinical and early clinical innovation engine of Novartis. Previously, Dr. Malek was Vice President of Discovery Oncology at Genentech, accountable for oncology research and the company’s targeted therapeutics oncology research portfolio. She joined Genentech in 2006 as one of the first scientists in its newly established small-molecule discovery team, and previously held positions of increasing responsibility at Vertex Pharmaceuticals and Exelixis. Dr. Malek is a world leader in RAS/RAF biology whose work has been critical to the discovery and validation of drug targets across multiple kinase signaling pathways in cancer. In 2021, she was selected by Endpoints as one of 20 top women leaders in biopharma R&D. She earned her Ph.D. in biochemistry from the University of California San Diego.
